B

Basilea Pharmaceutica
BSLN

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
CHF571.38M
EV
CHF539.80M
Shares Outstanding
12.29M
Beta
0.43
Industry
Biotechnology

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
Number of Analysts
5
P/E 2025E
15.23x
P/Revenue 2025E
2.60x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Basilea Pharmaceutica AG

gainify

B

Basilea Pharmaceutica AG

BSLN

Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develop...

Sector

Healthcare

Industry

Biotechnology

CEO

Veitch, David

Employees

180

IPO Date

2004-03-25

Headquarters

Hegenheimermattweg 167b, Allschwil 4123, Switzerland

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.